#SITCQuestfor100
With six transformative, innovative, and diverse strategic goals, SITC set a vision for 100 novel immuno-oncology agents approved by 2034. Join our quest to develop a diverse portfolio of agents, expand into earlier lines of therapy, explore AI solutions, and broaden our community tent.
Learn More